5 best EDC platforms for real-world evidence studies in 2026

Collecting longitudinal data across heterogeneous patient populations without the control structure of an interventional trial isn't a problem you solve with a conventional site-based EDC. You need a platform built to integrate data from electronic health records, patient-reported outcomes, wearables, and claims databases while maintaining the audit trail rigor regulators expect for post-market surveillance and registry submissions. Viedoc's EDC software supports real-world evidence studies with flexible data capture across 7,000-plus completed studies in 75-plus countries, delivering 99.99% uptime, modular ePRO and Televisit integration, and transparent study-based pricing that scales to multi-year observational programs without penalizing longitudinal patient follow-up. This comparison evaluates five EDC platforms for real-world evidence studies across data integration capability, protocol adaptability for mid-study changes, compliance credentials for regulatory submissions, and total cost of ownership for extended observational timelines.

Real-world evidence generation requires platforms that can adapt to evolving research questions, accommodate diverse data sources, and maintain data quality over months or years of follow-up. You're managing data from patients in routine clinical practice, not a protocol-defined visit schedule, which means your EDC needs to handle irregular data collection, remote patient engagement, and integration with external systems you don't control.

Enterprise clinical trial platforms built for tightly controlled interventional studies often over-engineer the data model for observational research, adding cost and configuration complexity that doesn't map to pragmatic trial workflows. Budget-conscious academic tools may lack the validation infrastructure and 21 CFR Part 11 compliance documentation you need for regulatory submissions. The platforms reviewed here represent the most frequently evaluated options for sponsors, CROs, and medical device companies running observational studies, registries, and post-market surveillance programs.

Best EDC platforms for real-world evidence studies: quick comparison

These five eClinical platforms represent the most evaluated options for sponsors, CROs, and medical device companies running observational studies, registries, and post-market surveillance programs, reviewed across data integration capability, protocol adaptability, compliance credentials, and longitudinal study support.

1. Viedoc

Viedoc's EDC software supports real-world evidence studies with adaptable data capture across diverse study designs, from long-term registries and post-market surveillance programs to hybrid trials combining interventional and observational elements. The platform's modular architecture integrates ePRO, Televisits, eSignature, and API-based external system connectivity, enabling seamless data flow from patient-generated inputs, electronic health records, lab systems, and third-party analytics platforms without manual reconciliation. Viedoc's no-code Designer allows protocol changes and form updates mid-study without disrupting ongoing data collection, a critical capability for observational research where research questions evolve as data accrues.

Viedoc's compliance posture supports regulatory submissions for post-market studies and real-world evidence programs across global jurisdictions. The platform is ISO 27001, ISO 9001, and SOC 2 Type II certified, with FDA 21 CFR Part 11, ICH-GCP, EU Annex 11, and GDPR compliance built in. Viedoc's Inspection Readiness Packet (VIRP) provides structured audit-ready documentation at no additional cost, accelerating regulatory review timelines. For medical device companies running Japan post-market surveillance studies, Viedoc's PMS module delivers native support for Japanese regulatory requirements, a unique capability among SMID-focused EDC platforms.

Viedoc's transparent study-based pricing model with unlimited user seats removes the cost friction of longitudinal observational programs where patient engagement extends across months or years. With 24/7 customer success support, 99.99% uptime hosted on Microsoft Azure, and deployment across 40-plus languages in 75-plus countries, Viedoc supports geographically distributed real-world evidence programs without regional infrastructure constraints.

"Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate. As a data manager, I am using Viedoc everyday for work and it has made my life so easy when it comes to exporting and reviewing data." — Khadija B., Enterprise

Verified proof points:

• Study scale: 7,000+ completed studies across 75+ countries; 1.6 million participants across 30,000+ sites
• Platform reliability: 99.99% uptime; hosted on Microsoft Azure
• Data integration: REST API and Connector service for integration with CTMS, labs, registries, and analytics platforms
• Language support: Available in 40+ languages
• Pricing model: Unlimited user seats; transparent study-based licensing with no per-user fees
• Compliance: ISO 27001, ISO 9001, SOC 2 Type II certified; FDA 21 CFR Part 11, ICH-GCP, GDPR, EU Annex 11, HIPAA attestation
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers
• Support: 24/7 customer success support across global offices

  Launch, manage, and monitor clinical trials faster with intuitive EDC clinical trial software that keeps you compliant and audit ready.

2. Castor EDC

Castor EDC offers a no-code electronic data capture platform with dedicated real-world evidence capabilities designed for observational studies, patient registries, and retrospective EMR chart reviews. The platform supports both prospective and retrospective RWE study designs, with automated data extraction from electronic medical records via FHIR-based API integration and HIPAA release pathways through its Castor Catalyst AI-powered automation platform. Castor's eConsent, ePRO, and remote patient monitoring modules integrate natively within a single system, reducing the tooling complexity typical of multi-vendor observational study stacks. The platform is positioned for sponsors running decentralized real-world evidence programs with distributed patient populations, offering mobile-first patient engagement interfaces and video-enabled informed consent for remote enrollment.

Castor maintains a REST API for custom integrations with external EMR/EHR systems, wearable devices, and eConsent solutions, though its formal technology partnership ecosystem is less developed than enterprise competitors. The platform supports CDISC data standards and offers flexible data management tools suited to protocol changes common in observational research. Castor is used primarily by academic researchers, medical device companies, and smaller biotech sponsors, with a strong presence in EU markets and growing US adoption.

3. Medidata Rave EDC

Medidata offers Rave EDC and Rave Lite, cloud-based electronic data capture systems supporting post-market observational studies, patient registries, and Phase IV trials alongside interventional clinical development programs. Rave EDC provides integration with eConsent, eCOA, and electronic health record data via Rave Companion, enabling automated population of EDC forms with EHR data to reduce manual site burden in real-world studies. As part of the Medidata Clinical Cloud suite, Rave EDC connects to RTSM, eTMF, CTMS, and safety modules, supporting unified data workflows for sponsors managing observational studies alongside traditional trial portfolios. Medidata Link enables trial data linkage to real-world data sources for cross-study analytics and external control arm generation.

Rave Lite is tailored for Phase I, Phase IV, and medical device post-market studies, offering a cost-effective and faster study build option while leveraging the same core Rave EDC infrastructure. With over 30,000 historical trials and 9 million patients across 100-plus countries in the Medidata platform, the system provides access to synthetic control arm generation and AI-powered protocol optimization using historical trial data. Medidata is the most widely deployed EDC globally, with over 700,000 certified site users, making it the de facto standard for large pharma and established CRO networks.

4. Veeva Vault EDC

Veeva offers Vault EDC, a modern cloud-based electronic data capture platform integrated with the Vault CTMS, eTMF, and pharmacovigilance suite, designed for life sciences companies managing longitudinal pharma studies across interventional and observational programs. Vault EDC supports protocol amendments and mid-study changes without downtime or data migration, a capability relevant to observational research where study scope evolves as data collection progresses. The platform uses drag-and-drop configuration tools to reduce study build timelines, with claims of study builds completing in as few as four weeks and user acceptance testing completing in half the time compared to legacy EDC systems.

Vault EDC is positioned for mid-to-large pharma sponsors and CROs already embedded in the Veeva ecosystem, where seamless integration with Vault eTMF, CTMS, and regulatory information management delivers workflow efficiencies unavailable from standalone EDC platforms. The platform supports over 1,000 study starts and is used by eight of the top 20 biopharma companies and two of the top six CROs. Veeva's CRO Partner Program provides certified training for CROs to configure studies independently, with 2–4 weeks of training and mentoring during first casebook builds.

5. Medrio

Medrio offers a user-friendly EDC platform supporting Phase I clinical trials, medical device studies, and observational research with a focus on ease of use, offline data capture, and mobile-first interfaces. The platform is designed for lean clinical teams running studies in resource-constrained environments, offering rapid deployment timelines and simplified training requirements compared to enterprise EDC systems. Medrio's offline capture capability enables data collection in settings without reliable internet connectivity, a relevant feature for global real-world evidence programs in emerging markets or rural clinical settings.

Medrio integrates with third-party ePRO, CTMS, and pharmacovigilance systems through partnerships with Lightship, Red Nucleus, Thoughtsphere, and Pharmaseal, though these integrations are not as extensively documented on the company website as competing platforms. The platform supports regulatory compliance for FDA and EMA submissions and is used primarily by Phase I CROs, medical device sponsors, and smaller biotech companies running early-phase or post-market observational studies.

What to look for in EDC platforms for real-world evidence studies

Data integration architecture and external system connectivity

Real-world evidence studies aggregate data from sources you don't control — electronic health records, claims databases, wearable devices, patient-generated health data, and third-party registries. Your EDC platform's integration capability determines whether you're manually reconciling CSV exports across systems or automating data flow through validated API connections. Look for REST API documentation, pre-built connectors for common EMR systems (Epic, Cerner, Allscripts), FHIR-based interoperability for EHR data retrieval, and webhook support for event-driven integrations with external analytics platforms. Platforms with single-vendor ePRO, eConsent, and Televisit modules integrated natively reduce tooling complexity and eliminate the data reconciliation overhead of multi-vendor stacks.

The quality of API documentation matters as much as the API itself. Poorly documented integrations create technical debt your IT team inherits, slowing deployment timelines and adding unpredictable costs for custom middleware development. Evaluate whether the platform maintains a formal technology partnership program with verified integrations to common RWE data sources, or whether integration capability exists only as theoretical REST API availability requiring custom build effort. Viedoc's API and Connector service supports validated integrations with CTMS, lab systems, IWRS, and analytics platforms, with modular ePRO, Televisits, and eSignature built into the same eClinical suite.

Weak integration architecture forces you into manual workflows that don't scale to multi-year observational programs. If your platform can't ingest structured EHR data without manual transcription, you've introduced site burden, data entry error risk, and compliance exposure that undermine the entire purpose of capturing real-world data.

Protocol adaptability and mid-study change management

Observational research questions evolve as data accrues. A registry tracking cardiovascular outcomes in a patient population may add new endpoints mid-study based on safety signals that emerge six months into data collection. Your EDC platform must support protocol amendments, form updates, and logic rule changes without taking the database offline or requiring full data migration. Legacy EDC platforms built for interventional trials often require vendor-side programmers to implement changes, creating bottlenecks where simple form additions take weeks to deploy and mid-study amendments incur substantial change-order fees.

Evaluate how the platform handles versioning, whether study amendments can be deployed incrementally without affecting live data collection, and whether data managers can make changes in-house using no-code configuration tools or must route all requests through vendor technical support. Platforms designed for RWE workflows should support conditional branching, dynamic form visibility based on patient characteristics, and longitudinal data models that accommodate irregular visit schedules without forcing every patient into a fixed protocol structure. Viedoc's no-code Designer enables certified data managers to configure studies and deploy amendments independently, with real-time validation rules that adapt to changing protocol requirements without vendor dependency.

Rigid platforms that require database downtime for amendments create operational risk in long-term studies where continuous data flow is critical. If updating a single data field requires taking your registry offline for three days, you're operating with the wrong tool.

Compliance infrastructure and regulatory inspection readiness

Real-world evidence submitted for regulatory decision-making faces the same audit scrutiny as interventional trial data. Your EDC platform must provide complete, exportable audit trails documenting every data entry, query resolution, and user action with timestamps and user credentials. FDA 21 CFR Part 11 compliance for electronic signatures, ICH-GCP adherence, GDPR and HIPAA compliance for patient data handling, and ISO 27001 or SOC 2 certification for information security are baseline requirements, not optional enhancements. Evaluate whether the platform provides pre-built computer system validation (CSV) documentation, structured inspection readiness packets, and regulatory submission support, or whether you're expected to generate validation evidence internally.

Platforms with formal Inspection Readiness Packets (VIRP) or equivalent audit-ready documentation accelerate regulatory review timelines by providing inspectors with structured evidence of system validation, data integrity controls, and quality management processes. Viedoc's VIRP is available to all customers at no additional cost, reducing the CSV workload that typically delays observational study go-live dates. For medical device companies running post-market surveillance programs in Japan, platform support for PMDA ERES compliance and Japanese regulatory workflows is a functional requirement, not a nice-to-have. Viedoc's Japan PMS module delivers native support for Japanese post-market surveillance regulatory requirements, a unique capability among modular EDC platforms.

Weak compliance infrastructure creates downstream validation burden your QA team must remediate manually. If your platform vendor can't produce validation evidence documentation on request, you're carrying regulatory risk that compounds with every study you deploy.

Total cost of ownership for long-term observational programs

Real-world evidence studies run for years, not months. Patient registries tracking long-term safety outcomes, post-market surveillance programs monitoring device performance across patient lifetimes, and pragmatic trials following patients under routine clinical care generate sustained platform costs that dwarf the initial implementation fee. Evaluate pricing models carefully — per-user licensing penalizes longitudinal studies where patient engagement extends across years, while per-study licensing with unlimited user seats aligns cost with study scope rather than headcount. Hidden fees for data storage, API calls, amendment support, or validation documentation can double the effective cost of ownership over multi-year programs.

Transparent pricing models where all costs are stated upfront enable accurate budget forecasting for long-term observational programs. Platforms that bundle platform hosting, software updates, customer success support, and validation documentation into a single study license reduce the risk of cost overruns from unexpected fees as studies evolve. Viedoc's study-based licensing includes unlimited user seats and 24/7 support, removing the cost friction of longitudinal patient follow-up where user counts fluctuate as participants engage remotely over time. For CROs managing multiple concurrent RWE programs, portfolio pricing that scales across studies without per-study multipliers can materially reduce total cost of ownership compared to platforms charging full license fees for each concurrent registry.

Opaque pricing structures force you to absorb cost uncertainty your CFO won't tolerate in multi-year budget planning. If your vendor can't provide all-in cost-per-study pricing upfront, you're negotiating change orders instead of running research.

How to choose the right EDC platform for real-world evidence studies

Step 1: Define your data source landscape and integration requirements

Map every external system that will feed data into your study — EMR/EHR systems, claims databases, wearable devices, third-party registries, lab systems, patient portals. Identify whether these systems expose FHIR APIs for structured data retrieval, require HIPAA release workflows for retrospective chart review, or operate as closed systems requiring manual data entry. Your platform's integration architecture must align with the data sources you're using, not the sources you wish you had. If 60% of your data comes from Epic EMR systems and your EDC can't ingest Epic data automatically, you're building manual workflows that won't scale.

Ask vendors for documented integration examples with the specific systems you're using. Generic claims of "REST API support" are insufficient — you need proof that the platform has successfully ingested data from your EMR vendor in a production RWE study, with validation evidence and compliance documentation you can review. Platforms with formal technology partnership programs and certified integrations reduce the technical risk of custom integration work.

Step 2: Assess protocol adaptability and study lifecycle flexibility

Real-world evidence studies rarely launch with complete protocol certainty. Research questions evolve, endpoints change, patient populations expand, and data collection instruments are added or modified as preliminary data accrues. Evaluate whether the platform supports protocol amendments without database downtime, whether data managers can deploy changes in-house using no-code tools, and whether the vendor charges change-order fees for routine protocol updates. Platforms that treat amendments as billable custom development work create cost and timeline friction incompatible with adaptive observational research.

Test the platform's configuration interface directly if possible. Drag-and-drop study builders marketed as "no-code" often require technical expertise equivalent to coding when implementing complex conditional logic or multi-arm study designs. If your data managers can't configure a realistic study form in under an hour during a demonstration, they won't be able to maintain the study independently once it's live.

Step 3: Validate compliance credentials and audit-readiness infrastructure

Request validation documentation, inspection readiness packets, and audit trail samples before committing to a platform. Review the audit trail export format to confirm it includes user credentials, timestamps, data field change logs, and query resolution history in a format regulators can review without proprietary software. Verify that the platform is certified to the compliance standards your study requires — ISO 27001 for information security, SOC 2 for operational controls, FDA 21 CFR Part 11 for electronic signatures, and region-specific requirements like GDPR for EU studies or HIPAA for US patient health information.

For medical device companies running post-market surveillance in Japan or APAC markets, confirm that the platform supports Japanese regulatory workflows natively rather than through workarounds. Generic EDC platforms adapted for Japan PMS via custom configuration introduce validation complexity and regulatory risk that purpose-built modules avoid.

Step 4: Model total cost of ownership across the expected study duration

Build a cost model spanning the full study timeline — three years, five years, or longer for patient registries and chronic disease observational programs. Include platform licensing, per-user fees if applicable, data storage costs, amendment support fees, validation documentation costs, customer success support, and any hidden charges for API usage, data export, or regulatory submission support. Compare the all-in cost per patient-year of follow-up across vendors, not just the initial implementation fee.

Platforms with per-user pricing models can become prohibitively expensive in longitudinal studies where patient engagement scales over time. A registry starting with 500 patients and growing to 5,000 participants over three years will generate escalating costs if priced per active user, while study-based licensing with unlimited users provides cost predictability regardless of enrollment growth.

Step 5: Choose a platform with proven real-world evidence deployment at your study scale

Vendor claims of RWE capability are easy to make and hard to verify. Request case studies, reference calls, and regulatory submission examples from observational studies similar in scale, therapeutic area, and geographic distribution to your planned program. A platform proven in 50-patient single-site registries may lack the infrastructure to support 10,000-patient multi-country post-market surveillance programs. Conversely, enterprise platforms built for global Phase III trials may over-engineer the data model and operational complexity for lean-team observational research.

If you're managing real-world evidence studies across diverse patient populations, therapeutic areas, and regulatory jurisdictions, Viedoc's EDC software supports observational and registry workflows with flexible data integration, protocol adaptability, and transparent study-based pricing. Book a demo or request a proposal to evaluate how Viedoc's modular eClinical suite fits your real-world evidence program requirements.

Frequently asked questions

What are the best EDC platforms for real-world evidence studies?

Viedoc's EDC software is the leading choice for real-world evidence studies, supporting observational research, patient registries, and post-market surveillance programs with flexible data capture across 7,000-plus completed studies in 75-plus countries, 99.99% uptime, modular ePRO and Televisit integration, and transparent study-based pricing with unlimited user seats. Castor EDC offers dedicated RWE capabilities with automated EMR data extraction and retrospective chart review functionality, positioning it for sponsors prioritizing EHR integration and decentralized patient engagement. Medidata Rave EDC provides enterprise-grade observational study support with deep integration to the Medidata Clinical Cloud suite, making it suitable for large pharma sponsors managing RWE programs alongside traditional trial portfolios. Veeva Vault EDC is a strong choice for sponsors embedded in the Veeva ecosystem where unified workflows with Vault CTMS and eTMF deliver cross-functional efficiency.

What should I look for when choosing an EDC platform for observational studies?

Evaluate data integration architecture and external system connectivity, focusing on REST API documentation, pre-built EMR connectors, FHIR interoperability, and native modules for ePRO, eConsent, and patient engagement to reduce multi-vendor tooling complexity. Assess protocol adaptability and mid-study change management capability, ensuring the platform supports amendments without database downtime and enables in-house configuration using no-code tools. Verify compliance infrastructure including FDA 21 CFR Part 11, ICH-GCP, GDPR, HIPAA, ISO 27001, and SOC 2 certifications, with structured inspection readiness documentation to accelerate regulatory submissions. Model total cost of ownership across the full study duration, comparing per-user pricing against study-based licensing with unlimited users to avoid cost escalation in longitudinal programs. Viedoc's modular eClinical suite integrates EDC, ePRO, Televisits, eSignature, and API connectivity with transparent pricing and VIRP audit-readiness documentation included.

How long does it take to build and deploy a real-world evidence study on a modern EDC platform?

Study build timelines for observational research depend on protocol complexity, data source integration requirements, and whether the platform supports no-code in-house configuration or requires vendor-side programming. Platforms with drag-and-drop study builders and pre-built form templates typically complete simple registry builds in 4–8 weeks, while complex multi-arm studies with conditional logic and external system integrations may require 10–16 weeks. Viedoc's no-code Designer enables certified data managers to configure studies in-house, with typical build timelines of 2–4 weeks for standard observational designs and faster deployment than enterprise platforms requiring vendor programmer involvement. Medidata Rave Lite positions faster study builds as a core differentiator for Phase I and Phase IV studies, while Veeva Vault EDC claims study builds in as few as four weeks using drag-and-drop configuration tools.

What compliance certifications should I look for in an EDC platform for regulatory-grade real-world evidence?

Real-world evidence submitted for regulatory decision-making requires the same audit trail rigor and compliance infrastructure as interventional trial data. Your EDC platform must provide FDA 21 CFR Part 11 compliance for electronic signatures, ICH-GCP adherence, GDPR compliance for EU patient data, HIPAA attestation for US protected health information, and ISO 27001 or SOC 2 certification for information security and operational controls. Platforms with structured Inspection Readiness Packets (VIRP) or equivalent audit-ready documentation accelerate regulatory submissions by providing inspectors with pre-built validation evidence. Viedoc is ISO 27001, ISO 9001, and SOC 2 Type II certified, with FDA 21 CFR Part 11, ICH-GCP, GDPR, EU Annex 11, and HIPAA compliance built in, and VIRP documentation available to all customers at no additional cost.

Which EDC platforms support Japan post-market surveillance studies for medical device companies?

Japan post-market surveillance (PMS) programs have unique regulatory requirements including booklet data collection, Kaifu process management, and PMDA ERES compliance that are not supported by most EDC platforms designed for Western pharma trials. Viedoc's Japan PMS module provides native support for Japanese post-market surveillance workflows, integrated within the Viedoc eClinical suite and accessible to anyone trained in the Viedoc Designer environment. The module handles booklet data collection, Kaifu review processes, progress management, query management, and regulatory reporting specific to Japanese PMS requirements, making it one of few modular EDC platforms with dedicated Japan post-market functionality. Medidata Rave Lite supports Phase IV and medical device post-market studies but does not advertise Japan-specific PMS capabilities, while Castor EDC and Veeva Vault EDC focus primarily on Western regulatory markets.

What is the difference between per-user and per-study EDC pricing for long-term observational programs?

Per-user pricing models charge based on the number of active users accessing the platform, which can escalate costs in longitudinal observational studies where patient enrollment grows over months or years and remote patient engagement requires additional user licenses. Per-study pricing with unlimited user seats charges a fixed fee per study regardless of user count, providing cost predictability for multi-year registries and post-market surveillance programs where patient populations and study team sizes fluctuate over time. Viedoc's transparent study-based licensing includes unlimited user seats, removing the cost friction of longitudinal patient follow-up and enabling accurate budget forecasting for extended observational timelines. Platforms with per-user pricing may offer volume discounts for large user counts but still expose sponsors to cost escalation risk as studies scale, while study-based licensing aligns cost with study scope rather than headcount.

Making the right EDC choice for real-world evidence studies

The platforms reviewed here span a range of deployment models, from Castor's RWE-specific automation capabilities and no-code academic accessibility, to Medidata's enterprise-grade Clinical Cloud integration and synthetic control arm generation, to Viedoc's modular eClinical suite balancing flexible data capture with regulatory compliance credentials. The global EDC market for real-world evidence and observational research is estimated at over $2 billion in 2025 and growing at approximately 16% annually, driven by regulatory acceptance of RWE for post-market surveillance, health technology assessment requirements, and payer demand for real-world effectiveness data beyond controlled trial populations.

Your platform choice should map to your organizational profile — study complexity, integration requirements, geographic distribution, regulatory jurisdiction, and internal technical capability. Sponsors running lean-team observational programs benefit from platforms with no-code configuration and native ePRO integration that reduce multi-vendor complexity, while large pharma organizations managing RWE portfolios alongside interventional trials may prioritize enterprise suite integration and cross-study analytics over standalone EDC flexibility. CROs supporting sponsor RWE programs require transparent pricing models that scale across concurrent studies without per-study cost multipliers, while medical device companies running Japan post-market surveillance need platforms with native PMS regulatory support rather than generic EDC systems adapted through workarounds.

Platform selection for multi-year observational programs carries higher switching costs than short-duration interventional trials. Validation burden, data migration complexity, and the regulatory risk of mid-program platform changes mean your initial EDC choice effectively locks in your technology stack for the duration of the study. Choose a platform with proven deployment scale at your study complexity, verified compliance credentials for your regulatory jurisdiction, and pricing transparency that enables accurate total cost of ownership forecasting across the full study timeline.

Why Viedoc is the best EDC choice for real-world evidence studies

If you're running observational research, patient registries, or post-market surveillance programs where data flows from diverse sources over months or years without the control structure of a protocol-defined visit schedule, Viedoc's EDC software delivers the flexible data capture, integration architecture, and compliance infrastructure you need. Viedoc supports 7,000-plus completed studies across 75-plus countries with 99.99% uptime, modular ePRO, Televisits, and eSignature integrated natively, and REST API connectivity for external system integration with CTMS, lab systems, registries, and analytics platforms.

Viedoc's no-code Designer enables certified data managers to configure studies and deploy protocol amendments in-house without vendor programmer dependency, reducing the bottlenecks common in observational research where research questions evolve as data accrues. With transparent study-based pricing and unlimited user seats, Viedoc removes the cost friction of longitudinal patient follow-up where enrollment scales over time and remote patient engagement requires flexible user access. ISO 27001, ISO 9001, and SOC 2 Type II certified, with FDA 21 CFR Part 11, ICH-GCP, GDPR, EU Annex 11, and HIPAA compliance built in, Viedoc provides the regulatory credentials and Inspection Readiness Packet (VIRP) documentation to support regulatory submissions and health authority inspections without additional validation burden.

For medical device companies running Japan post-market surveillance programs, Viedoc's PMS module delivers native support for Japanese regulatory workflows including booklet data collection and Kaifu process management, a unique capability among modular EDC platforms. With 24/7 customer success support, deployment across 40-plus languages, and a proven track record supporting real-world evidence programs for sponsors, CROs, and MedTech companies globally, Viedoc provides the operational reliability and compliance infrastructure long-term observational studies require. Book a demo or request a proposal to evaluate how Viedoc's modular eClinical suite supports your real-world evidence program.